医学
报告审判综合标准
替代医学
家庭医学
梅德林
四分位数
随机对照试验
传统医学
临床试验
系统回顾
荟萃分析
引用
医学杂志
医学文献
数据提取
研究设计
文献计量学
中医药
报告偏差
作者
Rui Zheng,Xiaowei Zhang,Yinghui Jin,Xinran Chen,Yaoyuan Yang,Hongcai Shang,Mitchell Levine
摘要
OBJECTIVE: To evaluate harms reporting practices in placebo-controlled randomized clinical trials (RCTs) of Chinese herbal medicine (CHM) formulas published in Quartile 1 (Q1) English-language and Tier-1 Chinese journals. METHODS: This systematic survey evaluated harms reporting in CHM formula RCTs. We systematically identified eligible RCTs published in English-language journals Q1 (2024 Journal Citation Reports) and Chinese Tier-1 journals (2023 Traditional Chinese Medicine ranking). Two reviewers independently evaluated harms reporting using items derived from the CONSORT Extension for Harms (CONSORT Harms) recommendations and CHM formula-specific reporting elements. RESULTS: Among 96 eligible RCTs (49 English Q1; 47 Chinese Tier-1), only 19.8% (n = 19) of trials had a published protocol, with a significantly higher proportion in English Q1 journals (p < 0.001). Only one trial explicitly reported adherence to the CONSORT Harms extension (2004 or 2022). Syndrome differentiation was significantly more frequent in Chinese Tier-1 journals than in English Q1 journals (76.6% vs. 38.8%, p < 0.001). Sixty-seven percent of studies (n = 64) did not report methods for assessing the relationship between harms and interventions, and 15.6% (n = 15) relied solely on clinical judgment. Eighty percent of studies (n = 77) did not report statistical methods for harms analysis. In the results section, 62% (n = 59) did not present harms data in tables. CONCLUSIONS: Harms reporting in CHM formula RCTs remains inadequate. Routine adoption of the CONSORT Harms framework, together with CHM formula-specific harms reporting elements, is needed to improve transparency and facilitate the interpretation of harms data in CHM formula research.
科研通智能强力驱动
Strongly Powered by AbleSci AI